請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52763
標題: | 以回溯性世代研究探討Cephamycin類抗生素造成低凝血酶原血症與出血風險 Use of Cephamycins and the Risk of Hypoprothrombinemia and Hemorrhagic Events: A Hospital-Based Retrospective Cohort Study |
作者: | Man-Ling Tung 董曼翎 |
指導教授: | 林淑文 |
關鍵字: | Cephamycin類抗生素,低凝血?原血症,出血事件,回溯性世代研究,醫院電子資料庫,病歷回顧, cephamycin,hypoprothrombinemia,hemorrhagic events,retrospective cohort study,electronic medical records, |
出版年 : | 2015 |
學位: | 碩士 |
摘要: | 研究背景: Cephamycin類抗生素包括cefmetazole及flomoxef廣泛用於治療社區型感染症以及術後傷口感染預防,然而過去有許多文獻顯示,其化學結構中帶有N-methylthiotetrazole(NMTT)及N-hydroxyethyltetrazolethiol(HTT)支鏈,可能造成低凝血酶原血症(hypoprothrombinemia),而引起凝血功能異常或出血事件副作用。過去相關研究僅有一篇cefmetazole造成的病例報告,近年有透過臺灣全民健康保險資料庫所做的嵌入型病例對照研究顯示cefmetazole與flomoxef與出血傾向增加之相關性。為彌補健保資料庫受限於缺乏實驗室檢驗數據,本回溯性世代研究透過國立臺灣大學醫學院附設醫院(簡稱臺大醫院)電子資料庫,探討cefmetazole與flomoxef的使用與低凝血酶原血症與出血事件副作用發生風險之相關性、嚴重程度,以及該副作用之風險因子。 研究方法: 本回溯性世代研究期間設定為2008年至2013年,納入條件為研究期間內年齡20歲以上、在臺大醫院急診或住院使用針劑劑型之cefmetazole與flomoxef (定義為study antibiotics);amoxicillin/clavulanate、ampicillin/sulbactam、cefuroxime、cefotaxime和ceftriaxone(定義為reference antibiotics)等抗生素48小時以上之治療記錄。 本研究將納入觀察對象開始使用抗生素當日定義為index date,觀察期間為index date至研究終點發生、抗生素種類變更或抗生素療程結束後第7天。研究終點定義為觀察期間內發生低凝血酶原血症(international normalized ratio,INR增加大於1.5倍)與出血相關事件(以ICD-9-CM code找出有出血診斷者後,透過病歷回顧確認發生於用藥後)。以Cox proportional hazard model計算出經風險因子校正之風險比(adjusted HR)與95 %信賴區間呈現抗生素與副作用發生風險的相關性。 研究結果: 本研究共納入22480位病人(26420筆療程記錄),其中,cefmetazole使用者共3543筆,flomoxef共3866筆,reference antibiotics共19011筆,平均年齡約64歲,以男性略占多數(59.0 %)。研究結果顯示,使用cefmetazole與發生低凝血酶原血症(adjusted HR 2.28; 95 % CI 1.82-2.86)及出血事件具統計上顯著相關(adjusted HR 2.80; 95 % CI 1.74-4.50),且發生低凝血酶原血症之風險隨著使用劑量增加而增加;flomoxef的使用則未顯著增加發生低凝血酶原血症或出血事件之風險。使用study antibiotics後發生之出血事件種類種以腸胃道出血(41.02 %)為最多,其次為泌尿生殖道出血(35.02 %)。 另外,病人於index date前7天或觀察期間內有使用過warfarin(adjusted HR 12.31; 95 % CI 8.47-17.88)、肝功能不全(adjusted HR 2.90; 95 % CI 2.32-3.84)、腎功能不全(adjusted HR 1.96; 95 % CI 1.55-2.48)、血中白蛋白低下(adjusted HR 1.81; 95 % CI 1.38-2.38)以及過去曾有肝炎或肝衰竭病史(adjusted HR 2.09; 95 % CI 1.64-2.65)等情況為此類藥品副作用發生之顯著風險因子。 結論: 由於使用cefmetazole相較於使用amoxicillin/clavulanate、ampicillin/sulbactam、cefuroxime、cefotaxime和ceftriaxone等抗生素顯著增加低凝血酶原血症與出血事件發生風險,尤其當病人有服用warfarin、肝腎功能不全、血中白蛋白低下以及過去有肝臟疾病史時,在處方這類抗生素時,應定期監測病人的國際標準化凝血酶原時間比值及出血症狀。 Background: Hypoprothrombinemia-inducing cephamycins that contain NMTT or HIT side chain are commonly prescribed in the treatment of community-acquired infections at National Taiwan University Hospital (NTUH). One case report and our previous study analyzing National Health Insurance Research Database (NHIRD) demonstrated a potential hemorrhagic tendency or event related to cefmetazole and flomoxef. Due to limitations of NHIRD including lack of lab results, we performed a retrospective cohort study to examine the association and severity of cephamycins and the risk of hypoprothrombinemia and hemorrhagic events using electronic medical records at NTUH. Methods: Adult patients receiving cefmetazole and flomoxef (study antibiotics) and IV amoxicillin/clavulanate, ampicillin/sulbactam, cefuroxime, cefotaxime and ceftriaxone (reference antibiotics) for more than 48 hours between 2008 and 2013 were included. Cox regression models were used to calculate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) for hypoprothrombinemia (INR >1.5 or longer than baseline) and bleeding events (hemorrhage-related ICD-9-CM code) occurring within 7 days after the end of antibiotic treatment. Results: We identified 22480 patients (26420 treatment courses) in the study period. A total of 3543 courses of cefmetazole, 3866 courses of flomoxef, and 19011 courses of reference antibiotics were included in the analysis. The patients’ average age was 64 years old and 59.0 % were male. The risks of hypoprothrombinemia were associated with study antibiotics use, renal dysfunction (aHR 1.96; 95 % CI 1.55-2.48) and hepatic dysfunction (aHR 2.90; 95 % CI 2.32-3.84), hypoalbuminemia (aHR 1.81; 95 % CI 1.38-2.38), co-medications such as warfarin (aHR 12.31; 95 % CI 8.47-17.88), and history of hepatitis or hepatic failure (aHR 2.09; 95 % CI 1.64-2.65). The aHRs of hypoprothrombinemia were 2.28 (95 % CI 1.82-2.86) in cefmetazole and 1.29 (95 % CI 0.99-1.68) in flomoxef. The aHRs were 2.80 (95 % CI 1.74-4.50) and 1.57 (95 % CI 0.86-2.88) for hemorrhagic events, respectively. The most common hemorrhagic sites were gastrointestinal tract (41.02 %), and 35.02 % of patients suffered from genitourinary hemorrhage. Conclusions: Close monitoring of INR levels in patients using cefmetazole is warranted, especially in patients who are taking warfarin, having renal or hepatic dysfunction and hypoalbuminemia. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/52763 |
全文授權: | 有償授權 |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.39 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。